Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease

[1] Griffith DE(2007)An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med 175 367-416

[2] Aksamit T(2010)Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems Am J Respir Crit Care Med 182 970-6

[3] Brown-Elliott BA(2010)Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease Am J Respir Crit Care Med 182 977-82

[4] Catanzaro A(1994)Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease Am J Respir Crit Care Med 149 1335-41

[5] Daley C(1999)Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease Am J Respir Crit Care Med 160 866-72

[6] Gordin F(2006)Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease Am J Respir Crit Care Med 174 928-34

[7] Prevots DR(2012)Macrolide antibiotics for cystic fibrosis Cochrane Database Syst Rev 11 CD002203-32

[8] Shaw PA(1998)Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin Am J Respir Crit Care Med 157 1829-98

[9] Strickland D(2011)COPD Clinical Research Network: azithromycin for prevention of exacerbations of COPD N Engl J Med 365 689-47

[10] Jackson LA(2008)Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations Am J Respir Crit Care Med 178 1139-9

[1] Griffith DE(2007)An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med 175 367-416

[2] Aksamit T(2010)Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems Am J Respir Crit Care Med 182 970-6

[3] Brown-Elliott BA(2010)Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease Am J Respir Crit Care Med 182 977-82

[4] Catanzaro A(1994)Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease Am J Respir Crit Care Med 149 1335-41

[5] Daley C(1999)Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease Am J Respir Crit Care Med 160 866-72

[6] Gordin F(2006)Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease Am J Respir Crit Care Med 174 928-34

[7] Prevots DR(2012)Macrolide antibiotics for cystic fibrosis Cochrane Database Syst Rev 11 CD002203-32

[8] Shaw PA(1998)Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin Am J Respir Crit Care Med 157 1829-98

[9] Strickland D(2011)COPD Clinical Research Network: azithromycin for prevention of exacerbations of COPD N Engl J Med 365 689-47

[10] Jackson LA(2008)Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations Am J Respir Crit Care Med 178 1139-9